General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Negotiations were not pursued
Manufacturer:
Ferring Canada Inc.
Indication:
Ulcerative Colitis
Last updated April 7, 2017
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Chronic Iron Overload
Last updated April 4, 2017
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Chronic Iron Overload
Last updated April 4, 2017
Status:
Negotiations were not pursued
Manufacturer:
Teva Canada Ltd.
Indication:
Pain (breakthrough), cancer (adults)
Last updated March 31, 2017
Status:
Concluded without agreement
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Schizophrenia and Related Psychotic Disorders
Last updated March 31, 2017
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Macular edema secondary to branch retinal vein occlusion
Last updated March 13, 2017
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
HIV-1 Infection
Last updated March 13, 2017
Entresto (sacubitril/valsartan)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Heart failure, NYHA class II or III
Last updated March 6, 2017
Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
Crohn's disease
Last updated March 3, 2017
Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
Ulcerative Colitis
Last updated March 3, 2017